Status:
TERMINATED
MK0767 in Metabolic Syndrome-Dyslipidemia (0767-016)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Metabolic X Syndrome Dyslipidemia
Eligibility:
All Genders
21-65 years
Phase:
PHASE2
Brief Summary
This is a clinical trial in patients with Metabolic Syndrome and Dyslipidemia to study the effects of MK0767 on triglycerides.
Eligibility Criteria
Inclusion
- Patients with Metabolic Syndrome and Dyslipidemia age 21 to 65
- Patients will be eligible for the study if their triglyceride levels are within protocol specified range and have at least 2 of the criteria for Metabolic Syndrome as defined by NCEP
Exclusion
- Patients with a history of diabetes mellitus, partial ileal bypass, intolerant to fibric acid derivatives, requiring continuous oral corticosteroids, taking anti-seizure medications, documented coronary heart disease, renal insufficiency, proteinuria, viral hepatitis, cholelithiasis or other gallbladder disease, pancreatitis, neoplastic disease
- Patient is on cyclical estrogen medications
- Patient has taken lipid-lowering agents including fibric acid derivatives, bile acid sequestrants, HMG CoA reductase inhibitors and nicotinic acid derivatives within 8 weeks or probucol within 1 year of prior to visit 2
Key Trial Info
Start Date :
January 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2003
Estimated Enrollment :
436 Patients enrolled
Trial Details
Trial ID
NCT00703690
Start Date
January 1 2002
End Date
December 1 2003
Last Update
June 12 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.